30 Day Trial

ORTHOKNOW content is posted to these pages in real time.

Monthly compilations are available in PDF form.

Quarterly Review

1Q13 Revenue: NuVasive

$159.5MM, +5% (Ex-U.S. +47%; U.S. cervical +13%, U.S. lumbar +1%, U.S. biologics -2%, U.S. monitoring services +3%)

  • Will make a $7.5MM upfront partial settlement payment in ongoing litigation with Medtronic regarding cervical plate patents, and gain broad access to Medtronic’s cervical plate portfolio; NuVasive will assume a royalty rate of 3% on certain plates that rely on patents licensed
  • Opened office in Tokyo
  • Medical device tax just over $1.6MM in the quarter